Vivos Therapeutics (NASDAQ:VVOS) Trading 1.5% Higher – Should You Buy?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares traded up 1.5% during trading on Wednesday . The company traded as high as $1.45 and last traded at $1.34. 257,368 shares traded hands during trading, an increase of 168% from the average session volume of 95,931 shares. The stock had previously closed at $1.32.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Ascendiant Capital Markets reduced their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, December 3rd. Zacks Research upgraded Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.92.

Vivos Therapeutics Price Performance

The stock has a market cap of $14.03 million, a P/E ratio of -0.76 and a beta of 6.94. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31. The company’s fifty day simple moving average is $1.62 and its 200-day simple moving average is $2.35.

Institutional Trading of Vivos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VVOS. Acorn Wealth Advisors LLC acquired a new position in Vivos Therapeutics in the fourth quarter worth about $30,000. XTX Topco Ltd acquired a new stake in Vivos Therapeutics during the second quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Vivos Therapeutics in the 2nd quarter valued at approximately $220,000. DRW Securities LLC grew its stake in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the period. Finally, Connective Capital Management LLC acquired a new position in shares of Vivos Therapeutics in the 3rd quarter worth approximately $620,000. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.